Brad Sullivan has over 25 years of trading, sales and business development experience for institutional buyside and sellside organizations. Mostly notedly long stints at Russell Investments, one of the largest asset managers on the west coast, and StoneX Group, a Fortune 100 financial services company. He currently works for a publicly traded biotech, Alzamend Neuro where he is the liaison to institutional and retail investors. Alzamend is clinical-stage, biopharmaceutical company developing effective treatments for psychiatric disorders which affect over 600 million people globally. When not working, Brad enjoys spending time and traveling with his wife and three daughters.